Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma.
Phase of Trial: Phase III
Latest Information Update: 22 May 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 29 Sep 2010 New trial record